---
schema_version: "secwatch.filing_event.v1"
accession: "0002007919-26-000044"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2026-08-13T20:10:15+00:00"
generated_at: "2026-08-13T20:12:44.893466+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Inhibrx Q2 net loss $36.7M; cash $219.5M post $100M Oxford loan; ozekibart PDUFA Apr 2027

## Summary
- Net loss $36.7M ($2.34/share) vs $28.7M ($1.85/share) in Q2 2025; no revenue vs $1.3M prior year.
- Cash $133.3M at June 30; $219.5M as of Aug 6 after $100M funded from $325M Oxford loan amendment.
- FDA accepted BLA for ozekibart in chondrosarcoma; PDUFA date April 14, 2027.
- INBRX-106 PFS data from Phase 2 HNSCC trial expected Q3 2026; new CRC cohorts initiated.
- R&D $23.9M, G&A $8.3M, up from $22.3M and $6.4M respectively.

## SEC filing metadata
- accession: 0002007919-26-000044
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2026-08-13T20:10:15+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/0002007919-26-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/inhibrx-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002007919-26-000044
- JSON: https://secwatch.observer/filing/0002007919-26-000044.json
- Plain text: https://secwatch.observer/filing/0002007919-26-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.